Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
NEW YORK, Dec. 16, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc. (NASDAQ:LGND) securities between November 9, 2015 and November 14, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/ligand-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Ligand you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/ligand-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
